Chemical stability of 4′-azidocytidine and its prodrug balapiravir

Drug Development and Industrial Pharmacy

Volumn 36, Issue 4, 2010, Pages 413-420

  Li, Fujun ^a   Wu, Xiaoyang ^b   Hadig, Xu ^b   Huang, Sujuan ^b   Hong, Lei ^b   Tran, Tony ^b   Brandl, Michael ^b   Alfredson, Tom ^b  

^a XenoPort Inc   (United States)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

Azide; Azido moiety; Initial rate method; Nucleoside analog; Prodrug

Indexed keywords

4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; AZIDE; BALAPIRAVIR; CYTOSINE; PRODRUG; UNCLASSIFIED DRUG; 4'-AZIDOCYTIDINE; ANTIVIRUS AGENT; CYTIDINE; NUCLEOSIDE;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUTION; DRUG STABILITY; DRUG SYNTHESIS; ELUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION PAIR CHROMATOGRAPHY; KINETICS; PH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STORAGE TEMPERATURE; ULTRAVIOLET RADIATION; ANALOGS AND DERIVATIVES; CHEMICAL REACTION; CHEMISTRY;

ANTIVIRAL AGENTS; AZIDES; CHEMICAL PROCESSES; CYTIDINE; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; NUCLEOSIDES; PRODRUGS;

EID: 77749304418     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903225075     Document Type: Article

References (25)

1. Klumpp K, Leveque V, Le Pogam S, Ma H, Jiang W-R, Kang H, et al. (2006). The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem, 281(7):3793-9.
2. Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, et al. (2007). Design, synthesis and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus placation: The discovery of R1479. Bioorg Med Chem Lett, 17:2570-6.
3. Smith DB, Kalayanov G, Sund C, Winqvist A, Pinho P, Maltseva T, et al. (2009). The design, synthesis, and antiviral activity of 4′-azidocytidine analogues against hepatitis C virus replication: The discovery of 4′-azidoarabinocytidine. J Med Chem, 52(1):219-23.
4. Brandl M, Wu X, Holper M, Hong L, Jia Z, Birudaraj R, et al. (2008). Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability. Drug Dev Ind Pharm, 34:683-91.
5. Li F, Maag H, Alfredson T. (2008). Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci, 97(3):1109-34.
6. Smith DB, Martin JA, Swallow S, Smith M, Kaiser A, Yee C, et al. (2006). From R1479 to R1626: Optimization of a nucleoside inhibitor of NS5B for the treatment of hepatitis C. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, September 10-14.
7. Alfredson T, Martin J, Swallow S, Smith D, Smith M, Kaiser A, et al. (2006). Design and evaluation of novel HCV polymerase inhibitor prodrugs with enhanced oral bioavailability. AAPS Annual Meeting and Exposition, Poster M1214.
8. Robson R, Berns H, Brandl M, Fettner S, Hill G, Ipe D, et al. (2007). Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting HCV polymerase: Results from a phase 1 single dose escalation trial in healthy subjects. Clin Pharmacol Ther, 81(Suppl. 1):S98.
9. Roberts S, Cooksley G, Shaw D, Berns HK, Brandl MT, Fettner SH, et al. (2006). Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J Hepatol, 44(Suppl. 2):S269.
10. Toniutto P, Fabris C, Bitetto D, Fumolo E, Fornasiere E, Pirisi M. (2008). R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs, 11(10):738-49.
11. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, et al. (2008). R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology, 48(2):385-97.
12. Chang S, Lamm SH. (2003). Human health effects of sodium azide exposure: A literature review and analysis. Int J Toxicol, 22(3):175-86.
13. Trout D, Esswein EJ, Hales T, Brown K, Solomon G, Miller M. (1996). Exposures and health effects: An evaluation of workers at a sodium azide production plant. Am J Ind Med, 30(3):343-50.
14. Brandl M, Strickley R, Bregante T, Gu L, Chan TW. (1993). Degradation of 4′-azidothymidine. Int J Pharm, 93:75-83.
15. Dunge A, Chakraborti AK, Singh S. (2004). Mechanistic explanation to the variable degradation behaviour of stavudine and zidovudine under hydrolytic, oxidative and photolytic conditions. J Pharm Biomed Anal, 35:965-70.
16. Maag H, Rydzewski RM, McRoberts MJ, Crawford-Ruth D, Verheyden JPH, Prisbe EJ. (1992). Synthesis and anti-HIV activity of 4′-azido- and 4′-methoxynucleosides. J Med Chem, 35(8):1440-51.
17. Juaristi E, Cuevas G. (1992). Recent studies of the anomeric effect. Tetrahedron, 48(24):5019-87.
18. Maag H, Nelson JT, Rios Steiner JL, Prisbe EJ. (1994). Solid-state and solution conformations of the potent HIV inhibitor, 4′-azidothymidine. J Med Chem, 37(4):431-8.
19. Taylor RB, Shivji ASH. (1987). A critical appraisal of drug stability testing methods. Pharm Res, 4(3):177-80.
20. Anderson BD, Taphouse V. (1981). Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. J Pharm Sci, 70(2):181-6.
21. Darrington RT, Jiao J. (2004). Rapid and accurate prediction of degradant formation rates in pharmaceutical formulations using high-performance liquid chromatography-mass spectrometry. J Pharm Sci, 93(4):838-46.
22. Zhivkova Z, Stankova I. (2000). Stability of some novel thymidine, 5-bromo-2′-deoxyuridine and 3′-azido-2′-3′- dideoxythymidine analogues. Int J Pharm, 200(2):181-5.
23. Amyes TL, Jencks WP. (1989). Lifetimes of oxocarbenium ions in aqueous solution from common ion inhibition of the solvolysis of α-azido ethers by added azide ion. J Am Chem Soc, 111(20):7888-900.
24. Swarin SJ, Waldo RA. (1982). Liquid chromatographic determination of azide as the 3,5-dinitrobenzoyl derivative. J Liq Chromatogr, 5(4):597-604.
25. Hong L, Hadig X, Tran T, Li F. (2007). Determination of trace level of free azide in R1626, a novel HCV polymerase inhibitor. AAPS Annual Meeting and Exposition, Poster W5025.